Advocating for Action in HCC: Delivering Impartial and Personalized Care

Advocating for Action in HCC: Delivering Impartial and Personalized Care

Advocating for Action in HCC: Delivering Impartial and Personalized Care
RestartResume

What do you need to know about establishing heath equity and improving care for patients with hepatocellular carcinoma?

Available credits: 1.00

Time to complete: 60 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Patients with advanced disease at diagnosis typically are not candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Additionally, liver cirrhosis and hepatic dysfunction often complicate treatment. Advances in the understanding of the molecular pathogenesis of HCC have broadened the potential for effective molecular targeted therapies, and advances in immune checkpoint inhibitor therapy are now transforming the way clinicians treat HCC.

    Of particular concern, HCC incidence and mortality rates have risen among American Indian/Alaska Native, Hispanic, and black populations in the United States in recent years. Incidence of HCC is also expected to increase in older populations due to hepatitis C, a risk factor for development of HCC, among other comorbid conditions such as cirrhosis, obesity, diabetes, and non-alcoholic steatohepatitis, which are also on the rise. Screening and surveillance of these conditions that contribute to the development of HCC occur less often in many Hispanic and black populations, which can delay diagnosis and leave them ineligible for curative resection or transplantation due to advanced disease, leading to worse prognosis.

    In this activity, the expert faculty will review health disparities, inequities, and care variations in HCC patients, and how to overcome these challenges to establish health equity for patients with HCC and reduce disproportionate patient outcomes. Recent therapeutic advances with immunotherapy and evidence-based treatment guideline recommendations will also be reviewed to ensure the optimal treatment of patients with HCC.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Describe health disparities in HCC that contribute to inequalities in health outcomes
    • Implement HCC screening and surveillance in racial and ethnic groups, disadvantaged populations, and in those at high risk for development of HCC to improve early detection and prognosis
    • Identify patient populations at risk of developing HCC to eliminate disparities in HCC care for all patients
    • Select appropriate treatment approaches for patients with HCC to help overcome disparities in care and promote health equity and improve QoL
  • Target Audience

    This activity is intended for the interprofessional care team composed of medical oncologists, pathologists, surgeons, gastroenterologists, hepatologists, pharmacists, physician assistants, oncology nurses, social workers, healthcare executives, human resources professionals, and others involved with the overall care coordination for hepatocellular carcinoma (HCC).

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: Monica L. Baskin, PhD, has no real or apparent conflicts of interest to report.  Josep M. Llovet, MD, PhD, reported a financial interest/relationship or affiliation in the form of Consultant: Eli Lilly and Co; Bayer HealthCare, Inc; Bristol-Myers Squibb Co; Eisai Inc; Celsion Corp; Exelixis, Inc; Merck & Co, Inc; Ipsen Pharmaceuticals; Genentech, Inc; Roche; Glycotest Diagnostics; Fortress Biotech, Inc; Nucleix; Can-Fite BioPharma; Sirtex; MiNA Therapeutics; and AstraZeneca Pharmaceuticals, LP. Research grant: Bayer HealthCare, Inc; Eisai Inc; Bristol-Myers Squibb Co; Boehringer Ingelheim; and Ipsen Pharmaceuticals.

    The planners, directors, managers, peer reviewers, and relevant staff  reported the following financial relationships they have ineligible companies: Linda Gracie-King, MS: Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC;  Adrienne N. Nedved, PharmD., MPA., BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships with any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.

  • Accreditation and Credit Designation Statements

    ACCREDITEDCONTINUING  EDUCATION
    Accreditation Statement

    ReachMD Healthcare ImageIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    ReachMD Healthcare ImageThis activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ReachMD Healthcare ImageCredit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 03/30/2022. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 1.0 contact hour of continuing pharmacy education credit JA4008106-0000-21-001-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Commercial Support

    This educational activity is supported by a medical education grant from Exelixis, Inc., and is supported by an educational grant from Genentech, a member of the Roche Group.

  • Terms of Use

    Disclosure of Unlabeled Use       
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer         
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:  
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free